Akero Therapeutics, Inc. (AKRO)
Automate Your Wheel Strategy on AKRO
With Tiblio's Option Bot, you can configure your own wheel strategy including AKRO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AKRO
- Rev/Share 0.0
- Book/Share 12.5526
- PB 3.7825
- Debt/Equity 0.0363
- CurrentRatio 12.6587
- ROIC -0.3023
- MktCap 3797876533.0
- FreeCF/Share -3.1011
- PFCF -14.9863
- PE -13.6644
- Debt/Assets 0.0335
- DivYield 0
- ROE -0.3157
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | AKRO | H.C. Wainwright | -- | Buy | -- | $72 | Sept. 4, 2025 |
| Initiation | AKRO | TD Cowen | -- | Buy | -- | $76 | Aug. 4, 2025 |
| Upgrade | AKRO | BofA Securities | Neutral | Buy | $35 | $63 | Jan. 30, 2025 |
| Reiterated | AKRO | H.C. Wainwright | -- | Buy | $50 | $72 | Jan. 27, 2025 |
News
Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?
Published: October 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Akero Therapeutics, Inc. (AKRO) and Humana (HUM) have performed compared to their sector so far this year.
Read More
5 Biotech Stocks Worth Adding to Your Portfolio Now
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Positive
The volatile biotech industry has done reasonably well so far in 2025 amid the ongoing tariff saga. Most pharma/biotech bigwigs are now investing heavily in manufacturing plants/operations in the United States as the Trump administration threatened of levying heavy tariffs on pharmaceutical imports (upto 250%) in a bid to boost domestic production.
Read More
Akero Therapeutics, Inc. (AKRO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Akero Therapeutics, Inc. (NASDAQ:AKRO ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 10:45 AM EDT Company Participants Andrew Cheng - President, CEO & Director Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Well, good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference.
Read More
Has Akero Therapeutics (AKRO) Outpaced Other Medical Stocks This Year?
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Akero Therapeutics, Inc. (AKRO) and Stryker (SYK) have performed compared to their sector so far this year.
Read More
Does Akero Therapeutics (AKRO) Have the Potential to Rally 59.14% as Wall Street Analysts Expect?
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 59.1% in Akero Therapeutics (AKRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Are Medical Stocks Lagging Akero Therapeutics (AKRO) This Year?
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Akero Therapeutics, Inc. (AKRO) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero"or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
Read More
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025, at 2:40 p.m. E.T.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation
Published: May 29, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero"or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Connect
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero"or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
Read More
Akero: FGF21 Advancement For MASH Targeting Presses On With Key Developments
Published: May 21, 2025 by: Seeking Alpha
Sentiment: Neutral
Akero Therapeutics' efruxifermin shows strong potential in MASH, especially compensated cirrhosis, with positive 96-week phase 2b data published in NEJM. The SYNCHRONY phase 3 program targets a broad MASH population, positioning Akero for significant market opportunity and acquisition interest. GlaxoSmithKline's $1.2B acquisition of FGF21 asset validates the value of Akero's approach and increases likelihood of a strategic buyout occurring.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero"or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect
Published: May 15, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero"or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
Read More
Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of treatment with efruxifermin (EFX)
Read More
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, presented results from the Phase 2b SYMMETRY trial demonstrating the potential of efruxifermin (EFX) to improve fibrosis in compensated cirrhosis (F4) caused by metabolic dysfunction-associated steatohepatitis (MASH), in a late-breaking oral presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7-10, in Amsterdam, the Netherlands.
Read More
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from SYMMETRY trial presented at EASL Congress 2025
Read More
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, presented results from the Phase 2b SYMMETRY trial demonstrating the potential of efruxifermin (EFX) to improve fibrosis in compensated cirrhosis (F4) caused by metabolic dysfunction-associated steatohepatitis (MASH), in a late-breaking oral presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7-10, in Amsterdam, the Netherlands.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Investors to Inquire about Securities Investigation
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero"or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Connect
Published: April 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation
Published: April 22, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
Read More
Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Published: April 17, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out
Published: April 15, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
Read More
Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Published: April 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect
Published: April 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation
Published: March 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out
Published: March 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Stockholders to Learn More About the Investigation
Published: March 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Investors to Inquire about Securities Investigation
Published: March 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
Read More
Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
-- Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study -- -- Completed enrollment of the double-blinded portion of the Phase 3 SYNCHRONY Real-World Study evaluating EFX in patients with either MASLD or MASH -- -- Presented New Analyses of Week 96 Phase 2b HARMONY in Patients with Pre-Cirrhotic (F2-F3) MASH at the 75th Annual AASLD The Liver Meeting® 2024 -- SOUTH SAN FRANCISCO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients …
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation
Published: February 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
Read More
About Akero Therapeutics, Inc. (AKRO)
- IPO Date 2019-06-20
- Website https://www.akerotx.com
- Industry Biotechnology
- CEO Andrew Cheng
- Employees 69